Opdivo did not meet primary endpoints in Phase III trials investigating the drug as a monotherapy for untreated advanced non-small cell lung cancer in patients whose tumors expressed PD-L1.
On August 5, 2016, Bristol-Myers Squibb’s (BMS) announced that its cancer drug Opdivo (nivolumab) did not meet primary endpoints in Phase III trials. The CheckMate -026 trial was investigating Opdivo as a monotherapy treatment for progression-free survival for patients with previously untreated advanced non-small cell lung cancer whose tumors expressed PD-L1.
Opdivo is FDA approved to treat patients with metastatic melanoma, classical Hodgkin Lymphoma, and those previously treated for advanced non-small cell lung cancer and advanced renal cell carcinoma. The drug was poised as a direct competitor for Merck’s Keytruda (pembrolizumab), an anti PD-L1 inhibitor, used to treat advanced melanoma and non-small cell lung cancer. The Wall Street Journal reported BMS shares fell 17% in the wake of the announcement, while Merck shares rose approximately 6.8%.
BMS released a statement early Friday saying they were disappointed in the results of the trial, but studying Opdivo as a combination therapy may be a promising outlet. The company’s CheckMate -227 trial is examining Opdivo in combination with Yervoy or in combination with chemotherapy, as a treatment for lung cancer patients. “We believe that combination therapy may provide an important opportunity to address the needs of every patient with first-line lung cancer,” BMS said in a statement.
Source: Bristol-Myers Squibb
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.